Clinical Trial Update: CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CNS10-NPC-GDNF delivered to the motor cortex in amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• CNS10-NPC-GDNF (GDNF-delivering neural progenitor cell therapy)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING